Primary Immunodeficiency: Clinical Trials

6 completed, 1 unknown. 7 Phase 4.

By phase and status

Phase	Trials	Status
Phase 4	7	Completed 6, Unknown 1

Follow Primary Immunodeficiency: new trials by email Literature Review of Primary Immunodeficiency trials Research Report on Primary Immunodeficiency

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID) IgPro - Primary Immunodeficiency	Phase 4	Completed	CSL Behring	8	2025-07-15	2026-07-16
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency IGSC 20% - Primary Immunodeficiency	Phase 4	Completed	Grifols Therapeutics LLC	33	2020-11-24	2023-09-29
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) IgPro20 - Primary Immunodeficiency	Phase 4	Completed	CSL Behring	49	2017-02-01	2020-03-25
IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia IgHy10 - Primary Immunodeficiency	Phase 4	Completed	University Hospital, Lille	22	2016-11-11	2019-06-25
A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push Chrono Super PID then Generic Syringe-Gammanorm, Generic Syringe then Chrono Super PID-Gammanorm - Primary Immunodeficiency	Phase 4	Completed	Octapharma	30	2015-07-29	2019-04-09
Diagnostic Immunization With Rabies Vaccine in Patients With PID Verorab® (PVRV; Purified Vero Cell Vaccine) - Primary Immunodeficiency	Phase 4	Unknown	Chulalongkorn University	40	2015-04-01	2015-07-07
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency GAMUNEX-C - Primary Immunodeficiency	Phase 4	Completed	Grifols Therapeutics LLC	12	2011-11-01	2015-03-13

Narrower conditions

Primary Immunodeficiency Diseases (7)  ·  Immune System Diseases (1)  ·  Immunologic Deficiency Syndromes (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7)  ·  Genetic Diseases, Inborn (7)  ·  Immune System Diseases (6)  ·  Immunologic Deficiency Syndromes (6)

Interventions

Hizentra (2)  ·  gamma-Globulins (2)  ·  Caprylates (1)  ·  Fluid Therapy (1)

Sponsors

CSL Behring (2)  ·  Grifols Therapeutics LLC (2)  ·  Chulalongkorn University (1)  ·  Octapharma (1)  ·  University Hospital, Lille (1)

Countries

United States (4)  ·  Australia (1)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Thailand (1)  ·  United Kingdom (1)

Top investigators

Eric Hachulla, MD, PhD (1)  ·  Klaus Warnatz, MD (1)

Results publications

PMID 27342758, PMID 33025378, PMID 33409867

NIH funding

2016 (2)